Evaluation of pimobendan and N-terminal probrain natriuretic peptide in the treatment of pulmonary hypertension secondary to degenerative mitral valve disease in dogs

Journal of Veterinary Internal Medicine

Volumn 23, Issue 6, 2009, Pages 1190-1196

  Atkinson, K J ^a,c   Fine, D M ^a   Thombs, L A ^b   Gorelick, J J ^b   Durham, H E ^a  

^a UNIVERSITY OF MISSOURI   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

^c Cardiology Northwest   (United States)

Author keywords

Cardiovascular; Echocardiography; Heart failure; Hemodynamics

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CARDIOTONIC AGENT; PEPTIDE FRAGMENT; PIMOBENDAN; PRO BRAIN NATRIURETIC PEPTIDE (1 76); PRO-BRAIN NATRIURETIC PEPTIDE (1-76); PYRIDAZINE DERIVATIVE;

ANIMAL; ANIMAL DISEASE; ARTICLE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOG; DOG DISEASE; DOUBLE BLIND PROCEDURE; MITRAL VALVE REGURGITATION; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL;

ANIMALS; CARDIOTONIC AGENTS; DOG DISEASES; DOGS; DOUBLE-BLIND METHOD; HYPERTENSION, PULMONARY; MITRAL VALVE INSUFFICIENCY; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PYRIDAZINES;

ANIMALIA; CANIS FAMILIARIS;

EID: 70350422573     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2009.0390.x     Document Type: Article

References (46)

1. Johnson L, Boon J, Orton EC. Clinical characteristics of 53 dogs with Doppler-derived evidence of pulmonary hypertension: 1992-1996. J Vet Intern Med 1999;13:440-447.
2. Serres FJ, Chetboul V, Tissier R, et al. Doppler echocardiog-raphy-derived evidence of pulmonary arterial hypertension in dogs with degenerative mitral valve disease: 86 cases (2001-2005). J Am Vet Med Assoc 2006;229:1772-1778.
3. Johnson L. Diagnosis of pulmonary hypertension. Clin Tech Small Anim Pract 1999;14:231-236.
4. Steele JL, Henik RA. Pulmonary hypertension. In: King L, ed. Textbook of Respiratory Disease in Dogs and Cats. St Louis, MO: WB Saunders; 2004:498-503.
5. Chatterjee K, De Marco T, Alpert JS. Pulmonary hypertension: Hemodynamic diagnosis and management. Arch Intern Med 2002;162:1925-1933.
6. MacDonald K, Johnson L. Pulmonary hypertension and pul-monary thromboembolism. In: Ettinger S, Feldman E, eds. Textbook of Veterinary Internal Medicine, 6th ed. St Louis, MO: Elsevier; 2005:1284-1288.
7. McLaughlin VV, Rich S. Pulmonary hypertension. Curr Probl Cardiol 2004; 29: 575-634
8. Johnson LR, Hamlin RL. Recognition and treatment of pulmonary hypertension. In: Bonagura JD, ed. Kirk's Current Veterinary Therapy XII. Philadelphia, PA: WB Saunders; 1995:887-892.
9. Pyle RL, Abbott J, MacLean H. Pulmonary hypertension and cardiovascular sequelae in 54 Dogs. Intern J Appl Res Vet Med 2004;2:99-109.
10. Boon J. Manual of Veterinary Echocardiography. Balti-more, MD: Lippincott Williams & Wilkins; 1998:179, 342-462.
11. Sisson DD. Neuroendocrine evaluation of cardiac disease. Vet Clin North Am 2004;34:1105-1126.
12. Lisy O, Redfield MM, Schirger JA, et al. Atrial BNP endocrine function during chronic unloading of the normal canine heart. Am J Physiol 2005;288:R158-R162.
13. Maack T. The broad homeostatic role of natriuretic peptides. Arquivos brasileiros de endocrinologia e metabologia 2006;50:198-207.
14. Andreassen AK, Wergeland R, Simonsen S, et al. N-terminal pro-B-type natriuretic peptide as an indicator of disease severity in a heterogeneous group of patients with chronic precapillary pulmonary hypertension. Am J Cardiol 2006;98:525-529.
15. Leuchte HH, El Nounou M, Tuerpe JC, et al. N-terminal probrain natriuretic peptide and renal insufficiency as predictors of mortality in pulmonary hypertension. Chest 2007;131:402-409.
16. Boswood A, Dukes-McEwan J, Loureiro J, et al. The diagnostic accuracy of different natriuretic peptides in the investigation of canine cardiac disease. J Small Anim Pract 2007;49:26-32.
17. Fine DM, Declue AE, Reinero CR. Evaluation of circulating amino terminal-pro-B-type natriuretic peptide concentration in dogs with respiratory distress attributable to congestive heart failure or primary pulmonary disease. J Am Vet Med Assoc 2008;232:1674-1679.
18. Oyama MA, Fox PR, Rush JE, et al. Clinical utility of serum N-terminal pro-B-type natriuretic peptide concentration for identifying cardiac disease in dogs and assessing disease severity. J Am Vet Med Assoc 2008;232:1496-1503.
19. Pagel PS, Hettrick DA, Warltier DC. Comparison of the effects of levosimendan, pimobendan, and milrinone on canine left ventricular-arterial coupling and mechanical efficiency. Basic Res Cardiol 1996;91:296-307.
20. Pagel PS, Hettrick DA, Warltier DC. Influence of levosimendan, pimobendan, and milrinone on the regional distribution of cardiac output in anaesthetized dogs. Br J Pharmacol 1996;119: 609-615.
21. Ohte N, Cheng CP, Suzuki M, et al. The cardiac effects of pimobendan (but not amrinone) are preserved at rest and during exercise in conscious dogs with pacing-induced heart failure. J Pharmacol Exp Ther 1997;282:23-31.
22. van Meel JC, Diederen W. Hemodynamic profile of the cardiotonic agent pimobendan. J Cardiovasc Pharmacol 1989;14(Suppl 2):S1-S6.
23. Watanabe E, Shiga T, Matsuda N, et al. Low-dose systemic phosphodiesterase III inhibitor pimobendan combined with prostacyclin therapy in a patient with severe primary pulmonary hypertension. Cardiovasc Drugs Ther 2003;17:375-379.
24. Nakatani M, Shirotani T, Kobayashi K, et al. Effects of low dose pimobendan in patients with corpulmonale. J Cardiol 1999;34:79-83.
25. Yamazaki Y, Matsumoto H, Takeda A, et al. Effects of pimobendan on pulmonary hypertension in patients with chronic pulmonary emphysema. Nihon Kyobu Shikkan Gakkai Zasshi 1997;35:847-853.
26. Shiga T, Wakaumi M, Yajima T, et al. Betablocker therapy combined with low-dose pimobendan in patients with idiopathic dilated cardiomyopathy and chronic obstructive pulmonary disease: Report on two cases. Cardiovasc Drugs Ther 2002;16:259-263.
27. Sahara M, Takahashi T, Imai Y, et al. New insights in the treatment strategy for pulmonary arterial hypertension. Cardiovasc Drugs Ther 2006;20:377-386.
28. Bach JF, Rozanski EA, MacGregor J, et al. Retrospective evaluation of sildenafil citrate as a therapy for pulmonary hyper-tension in dogs. J Vet Intern Med 2006;20:1132-1135.
29. Kellum H, Stepien R. Sildenafil citrate therapy in 22 dogs with pulmonary hypertension. J Vet Intern Med 2007;21:1258-1264.
30. O'Sullivan M. Pulmonary hypertension. In: Mathews K, ed. Veterinary Emergency and Critical Care Manual. Guelph, ON: Lifelearn; 2006:189-193.
31. Schmidt MK, Reynolds CA, Estrada AH, et al. Effect of azotemia on serum N-terminal proBNP concentration in dogs with normal cardiac function: A pilot study. J Vet Cardiol 2009;11:S81-S86.
32. Thomas W, Gaber C, Jacobs G, et al. Recommendations for standards in tranthoracic two-dimensional echocardiography in the dog and cat. Vet Radiol Ultrasound 1994;35:173-178.
33. Serres F, Chetboul V, Gouni V, et al. Diagnostic value of echo-Doppler and tissue Doppler imaging in dogs with pulmonary arterial hypertension. J Vet Intern Med 2007;21:1280-1289.
34. Schober KE, Baade H. Doppler echocardiographic prediction of pulmonary hypertension in West Highland White Terriers with chronic pulmonary disease. J Vet Intern Med 2006;20:912-920.
35. Tilley LP. Essentials of Canine and Feline Electrocardiography, 3rd ed. Philadelphia, PA: Lea & Febiger; 1992, p.172.
36. Buchanan JW, Bucheler J. Vertebral scale system to measure canine heart size in radiographs. J Am Vet Med Assoc 1995;206:194-199.
37. Lombard CW, Jons O, Bussadori CM. Clinical efficacy of pimobendan versus benazepril for the treatment of acquired atrio-ventricular valvular disease in dogs. J Am Anim Hosp Assoc 2006;42:249-261.
38. Freeman LM, Rush JE, Farabaugh AE, et al. Development and evaluation of a questionnaire for assessing health-related quality of life in dogs with cardiac disease. J Am Vet Med Assoc 2005;226:1864-1868.
39. Haggstrom J, Boswood A, O'Grady M, et al. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: The QUEST study. J Vet Intern Med 2008;22:1124-1135.
40. Hatle L, Angelson B. Doppler Ultrasound in Cardiology: Physical Principles and Clinical Application. Philadelphia, PA: Lea & Febiger; 1982:113-116.
41. O'Callaghan DS, McNeil K. Pulmonary hypertension and left heart disease: Emerging concepts and treatment strategies. Int J Clin Pract 2008;62:29-31.
42. Tarnow I, Olsen LH, Kvart C, et al. Predictive value of natriuretic peptides in dogs with mitral valve disease. Vet J 2009;180:195-201.
43. Gan CT, McCann GP, Marcus JT, et al. NT-proBNP reflects right ventricular structure and function in pulmonary hypertension. Eur Respir J 2006;28:1190-1194.
44. Kellihan HB, Oyama MA, Reynolds CA, Stepien RL. Weekly variability of plasma and serum NT-proBNP measurements in normal dogs. J Vet Cardiol 2009;11:S93-S97.
45. O'Hanlon R, O'Shea P, Ledwidge M, et al. The biologic variation of B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide in stable heart failure patients. J Card Fail 2007;13:50-55.
46. Borgarelli M, Savarino P, Crosara S, et al. Survival characteristics and prognostic variables of dogs with mitral regurgitation attributable to myxomatous valve disease. J Vet Intern Med 2008;22:120-128.